OncoMatch/Clinical Trials/NCT05312801
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Is NCT05312801 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BAFF CAR-T for lymphoma, non-hodgkin lymphoma, b-cell.
Treatment: BAFF CAR-T — Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
relapsed after 2 or more lines of therapy or disease refractory to chemotherapy
Cannot have received: autologous stem cell transplant
Exception: disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT)
disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT)
Cannot have received: autologous stem cell transplant
ASCT within 6 weeks of informed consent
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Cannot have received: investigational agent
Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection
Lab requirements
Kidney function
Serum creatinine < 1.5 mg/dL
Liver function
Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome); AST/ALT ≤ 2.5 X institutional upper limit of normal
Cardiac function
Cardiac ejection fraction of >50%, and no evidence of pericardial effusion, as determined by an echocardiogram
Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome). Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal. Serum creatinine < 1.5 mg/dL. Cardiac ejection fraction of >50%, and no evidence of pericardial effusion, as determined by an echocardiogram. Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Seidman Cancer Center · Cleveland, Ohio
- Taussig Cancer Institute | Cleveland Clinic · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify